David Sourdive

Elaia is an active, long-term manager which invests in software technology companies, primarily in France and on a case by case basis in other European countries. The firm typically invests €1-€2 million, alone or through syndicated rounds, allocating additional financing to the future financing needs of the investee company. Elaia's investment strategy aims to maximize diversification within software-related technologies. They seek to create a balanced portfolio allocation based on four diversification criteria: development stage, geographical location, economic model and market segment. The firm invests in companies in all development stages, with an emphasis on first rounds of venture capital and the ability to participate in special situations. This multi-stage approach generates a broad range of risk/reward profiles and different exit perspectives. They diversify by sector and economic model to address the widest range of opportunities within the software-related field. By diversifying geographically, they aim to allocate approximately 20% of their portfolio to European opportunities outside France, to provide better access to an international network and enlarge their understanding of the markets. Elaia participates as lead investor or as a follower in a syndicate, typically seeking a board position to accompany the management team through the key stages of the investee company's development, aiming to add value to the company. The firm seeks to invest in innovative, well-managed, high-growth companies in large, appealing markets, which meet customer's needs, ideally have an existing customer base, a realistic and sustainable business model and reasonable company valuation.

Operates as a stem cell contract development and manufacturing organization

Manufactures antibody-drug conjugates

Operates as clinical-stage biopharmaceutical company, which develops probiotics

Develops yeast for the production of chemical compounds

Founded in 2024, Omics SAS is a French biotechnology company focused on developing foundation AI models for biology, with an emphasis on plant biology. The company is based in Paris, France. The company's flagship product, Botanic, is a family of AI models for plant genomics, beginning with Botanic-0—a model with 1 billion parameters trained on over 1,600 curated plant genomes. Botanic-0 predicts gene functions, regulatory elements, and trait associations, aiming to accelerate the crop trait discovery process.

Produces and sales stem cells